Scientific Advisory Board

AnaptysBio’s scientific advisory board is involved in advancing the company’s SHM-XEL™ technology platform and its broad applications in antibody generation and protein engineering.

Matthew Scharff, M.D.
Albert Einstein College of Medicine

Dr. Scharff first worked as a Research Associate at the NIH before he joined the Departments of Cell Biology and Medicine at the Albert Einstein College of Medicine, where he has served as the Chairman of the Department of Cell Biology, Director of the Division of Biological Sciences and Director of the Cancer Center.

Dr. Scharff has devoted most of his research career to studying the production of antibodies by B cells, the role of antibodies in resistance to infection and in causing autoimmunity and the mechanisms responsible for the generation of antibody diversity. He is currently the Harry Eagle Professor of Cancer Research and a Distinguished Professor at the Albert Einstein College of Medicine. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences and has received numerous awards including the American Association of Immunologists Award for Excellence in Mentoring in 1998 and the Mayor of New York’s Lifetime Achievement Award for Excellence in Science and Technology, 2003.

Dr. Scharff received his undergraduate education from Brown University and was awarded an honorary Doctor of Medical Sciences degree from that University in 1994. He received his MD from New York University School of Medicine and was a house officer in medicine for the Harvard Service at the Boston City Hospital.

Phillip Patten, Ph.D.
Pioneer Hi-Bred International, Inc.

Dr. Patten currently holds the position of senior research fellow at Pioneer Hi-Bred International, Inc.  Previously, Dr. Patten served as senior vice president of biology at Achaogen, Inc., and as vice president of science and technology at Maxygen, where he was a founding scientist and developed the company’s gene shuffling technology.  He earned his bachelor’s degree in biology at the California Institute of Technology and his Ph.D. at Stanford University.  He was awarded a Damon Runyon Postdoctoral Fellowship at U.C. Berkeley where he did pioneering work on the structural basis of antibody affinity maturation.

Dennis R. Burton, Ph.D.
The Scripps Research Institute, La Jolla

Dennis Burton is Professor of Immunology and Microbiology at the Scripps Research Institute in La Jolla, California; Member of the Steering Committee of the Ragon Institute of MGH, MIT and Harvard; Scientific Director of the Neutralizing Antibody Consortium of the International AIDS Vaccine Initiative and Director of the NIH Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery at The Scripps Research Institute. He received a B.A. degree in Chemistry from the University of Oxford and a Ph.D. degree in nuclear magnetic resonance in biology from the University of Lund, Sweden. His early work focused on understanding antibody effector function and he was one of the co-discoverers of the complement and Fc receptor binding sites on immunoglobulin G.